Key result
Pharmacological inhibition and RNA interference of MMP-2 attenuated angiotensin II-induced hypertension in mice, without influencing development of cardiac hypertrophy or fibrosis.
Why the study?
Does inhibition of MMP-2, MMP-7, or TACE prevent angiotensin II-induced hypertension, cardiac hypertrophy, and fibrosis in mice?
Does inhibition of MMP-2, MMP-7, or TACE prevent angiotensin II-induced hypertension, cardiac hypertrophy, and fibrosis in mice?
MMP-2 specifically mediates angiotensin II-induced hypertension downstream of MMP-7 and TACE, but does not mediate cardiac hypertrophy or fibrosis, highlighting functional specialization of MMPs.
Answers are grounded in this paper and cite their sources.
MMP-2 inhibition may selectively attenuate Ang II hypertension in mice; hypothesis-generating for human translation and leaves cardiac remodeling effects open.
Development of cardiovascular disease induced by excessive Gq protein-coupled receptor agonist stimulation depends on signaling networks involving multiple matrix metalloproteinases (MMPs) and metalloproteinase disintegrins (ADAMs). Here, we hypothesized that MMP-2, being a major gelatinase in cardiac and vascular tissue, was likely to play a key role in cardiovascular homeostasis. We targeted MMP-2 using complementary and overlapping approaches involving pharmacological inhibition and RNA interference in mice treated with angiotensin II (1.4 mg/kg per day) for 12 days. We studied the development of hypertension (by tail cuff plethysmography), cardiac hypertrophy (by M-mode echocardiography, cardiomyocyte cross-sectional area, and quantitative real-time polymerase chain reaction (qRT-PCR) analysis of hypertrophy marker genes), and fibrosis (by picrosirius red collagen staining and qRT-PCR analysis of fibrosis marker genes) in mice receiving angiotensin II. We found that angiotensin II infusion upregulated MMP-2 concurrent with the development of hypertension, hypertrophy, and fibrosis. This upregulation of MMP-2 depended on MMP-7 and TACE (tumor necrosis factor-α convertase, ADAM-17). RNA interference targeting MMP-7 and TACE attenuated the angiotensin II-induced upregulation of MMP-2 and prevented the development of hypertension, as well as development of cardiac hypertrophy and fibrosis. In contrast, pharmacological inhibition and RNA interference of MMP-2 attenuated angiotensin II-induced hypertension, without influencing development of cardiac hypertrophy or fibrosis. Downstream of MMP-7 and TACE, MMP-2 mediated angiotensin II-induced hypertension, but did not mediate cardiac hypertrophy or fibrosis. This suggests a functional specialization of MMP-2 in agonist-induced cardiovascular disease development that has potential implications for the design of metalloproteinase-based therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Odenbach et al. (2010) studied Angiotensin II-induced hypertension, cardiac hypertrophy, and fibrosis. Pharmacological inhibition and RNA interference of MMP-2 was evaluated on Development of hypertension, cardiac hypertrophy, and fibrosis. Pharmacological inhibition and RNA interference of MMP-2 attenuated angiotensin II-induced hypertension in mice, without influencing development of cardiac hypertrophy or fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: